The FDA approved ofatumumab (Arzerra) for the treatment relapsed chronic lymphocytic leukemia (CLL).
Filgrastim-sndz, a biosimilar product to the G-CSF filgrastim, appears to be effective in the prevention of febrile neutropenia.
The rolling submission of the New Drug Application to the FDA for brigatinib is complete.
Gene expression that causes chromosomal instability may predict which patients with lung or breast cancer are likely to respond to chemotherapy and radiotherapy.
European patients with chronic myeloid leukemia who have high EUTOS risk scores achieved response much later than patients with low EUTOS risk scores.
Retinoic acid might have a role in suppressing colorectal cancer (CRC).
Informal caregiver well-being is associated with patient-perceived quality of care (QOC).
FDG-PET testing that shows early progression of patients with Ewing sarcoma is linked to reduced overall survival.
CTA has updated its treatment regimen chart for the treatment of renal cell carcinoma to reflect NCCN Guidelines for Kidney Cancer.
Minimal residual disease (MRD) assessment improves prediction of progression-free survival for patients with chronic lymphocytic leukemia (CLL).
Care at radiation oncology centers with a higher volume is associated with improved survival among patients with squamous cell carcinoma of the anal canal.
Women with early-stage breast cancer who perceive greater barriers to treatment with aromatase inhibitors (AIs) may be less likely to adhere to regimens.
CTA has updated its treatment regimen chart for the treatment of head and neck cancer to reflect changes put forth by Version 1.2016 of the NCCN Guidelines for Head and Neck Cancers.
Pacritinib, an investigational oral multikinase inhibitor, improves spleen volume reduction among high-risk patients with advanced myelofibrosis.
Alternative metrics of response correlated with the overall survival benefit among patients with RAS wild-type metastatic colorectal cancer (mCRC).
SLNB are more reliable PET-CT for assessing lymph node metastases among young patients with sarcoma.
The HSD3B1 (1245C) allele is linked to androgen deprivation therapy (ADT) resistance among patients with prostate cancer.
Addition of ifosfamide and etoposide to adjuvant cisplatin, doxorubicin, and high-dose methotrexate (MAP) did not improve event-free survival.
For patients with metastatic castration-resistant prostate cancer (mCRPC), 8 cycles of docetaxel may improve superior overall survival.
Adjuvant chemotherapy is beneficial for patients with locally-advanced, postoperative rectal cancer.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- PAP Series: Patient Assistance Programs "Culprits" of Rising Drug Prices
- Sleep Cycle May Be a Causal Factor of Chronic Lymphocytic Leukemia
- Continuing Docetaxel Therapy May Improve Survival in Prostate Cancer
- FDA Grants Priority Review for Rucaparib as Treatment for Advanced Ovarian Cancer
- New Mechanism of Treatment Resistance in BRAF-Mutant Melanoma Identified
- FDA Approves Ofatumumab With Chemo for Relapsed CLL
- Biosimilar G-CSF Effective in Preventing Febrile Neutropenia in Sarcoma
- Brigatinib NDA Submission Complete for ALK+ Metastatic NSCLC
- New Scoring System Accurately Identifies Patients Likely to Respond to Treatment
- Air Pollution May Affect Survival of Lung Cancer